Veterans with amyotrophic lateral sclerosis (ALS) are calling for the U.S. Food and Drug Administration (FDA) to hold a public advisory committee meeting to discuss the benefits of NurOwn — an investigational cell-based therapy that military service members say has slowed their disease. The request follows the regulatory…

Note: This story was updated Nov. 30, 2022, to indicate six patients in the Phase 2a part of FOCUS-C9 will receive a monthly 10 mg dose of WVE-004 over four months. An ongoing clinical trial of Wave Life Sciences’ WVE-004 in people with amyotrophic lateral sclerosis (ALS) and…

My husband, Todd, and I had a stressful night last week. While his nighttime caregiver was getting him ready for bed, Todd felt a rattle in his chest. He hoped that it would settle down once he was in bed. He’s often able to clear his lungs himself…

Have you ever thought about what a single breath means to you? What you can do in one breath? What you can say with one breath? What or whom you can see during one breath? We who suffer from respiratory problems give considerable thought to these questions. On three occasions…

Last weekend, my husband, Todd, and I watched the movie “The Electrical Life of Louis Wain,” about an eccentric artist in Victorian England. Wain’s comical and endearing illustrations of cats changed people’s perceptions of them and led to them being more accepted as household pets. From the description,…

NeuroSense Therapeutics has received the go-ahead to begin enrolling patients in the U.S. and Italy for a Phase 2b clinical trial testing PrimeC, the company’s experimental therapy for amyotrophic lateral sclerosis (ALS). The clinical trial, called PARADIGM (NCT05357950), enrolled its first participant in June. The study is…

A Phase 1/2 clinical trial is investigating the long-term safety and tolerability of BIIB105, Biogen‘s investigational treatment targeting the ataxin-2 protein, in people with amyotrophic lateral sclerosis (ALS). Called ALSpire (NCT04494256), the trial is currently recruiting adults with ALS at 12 sites in the U.S., Canada, and…

“Find the victory in this.” For nearly three decades, I’ve carried these five provocative words in my mind. Like my life, their meaning to me has evolved over time. I first heard them spoken at the funeral of a young woman, and the comment was directed to her 15-year-old son,…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Stealth Biotherapeutics’ investigational therapy SBT-272 for the treatment of amyotrophic lateral sclerosis (ALS). Aimed at speeding the development of new treatments for rare, life-threatening diseases, orphan drug status offers regulatory support and certain financial incentives…

I must confess, whenever I’m in a crowded public place, I wear a face mask. Why? Because I’m a person living with ALS and doing everything I can to keep my immune system in tiptop shape. Plus, being the only person wearing a mask doesn’t bother me. In fact,…